Kamal Shah1, Lillian Mellars2, Arun Changolkar3, Steven R Feldman4. 1. EMD Serono, Inc, Billerica, Massachusetts. Electronic address: dr.kamal.s.shah@gmail.com. 2. Celgene Corporation, Summit, New Jersey. 3. EMD Serono, Inc, Billerica, Massachusetts. 4. Department of Dermatology, Wake Forest University School of Medicine, Winston-Salem, North Carolina.
Abstract
BACKGROUND: Understanding background comorbidity rates in psoriasis can provide perspective for adverse events associated with new therapies. OBJECTIVE: We sought to assess the extent of comorbidities in psoriasis patients by use of the Truven Health Analytics MarketScan database. METHODS: MarketScan, comprising commercial claims representative of a large US-insured population, had 1.22 million patients with ≥1 claim with a psoriasis diagnosis between January 1, 2008, and December 31, 2014. Patients ≥18 years of age who had ≥2 health claims in any diagnosis field for psoriasis (International Classification of Diseases, 9th Revision, Clinical Modification 696.1) with a psoriasis diagnosis (index) date between July 1, 2008, and June 30, 2014, were included to allow follow-up observation time. RESULTS: Prevalence and incidence of 24 comorbidities were assessed in 469,097 psoriasis patients; the most common comorbidities were hyperlipidemia (45.64% and 30.83%, respectively), hypertension (42.19% and 24.19%), depression (17.91% and 12.68%), type 2 diabetes mellitus (17.45% and 8.44%), and obesity (14.38% and 11.57%). LIMITATIONS: A limitation of the study was that only a certain insured population was represented. CONCLUSIONS: Comorbidity rates align with those described in the literature and support the concept that psoriasis patients have high rates of cardiometabolic comorbidities. This analysis highlights the potential utility of very large insurance databases for determining comorbidity prevalence in psoriasis, which may aid health care providers in managing psoriasis.
BACKGROUND: Understanding background comorbidity rates in psoriasis can provide perspective for adverse events associated with new therapies. OBJECTIVE: We sought to assess the extent of comorbidities in psoriasispatients by use of the Truven Health Analytics MarketScan database. METHODS: MarketScan, comprising commercial claims representative of a large US-insured population, had 1.22 million patients with ≥1 claim with a psoriasis diagnosis between January 1, 2008, and December 31, 2014. Patients ≥18 years of age who had ≥2 health claims in any diagnosis field for psoriasis (International Classification of Diseases, 9th Revision, Clinical Modification 696.1) with a psoriasis diagnosis (index) date between July 1, 2008, and June 30, 2014, were included to allow follow-up observation time. RESULTS: Prevalence and incidence of 24 comorbidities were assessed in 469,097 psoriasispatients; the most common comorbidities were hyperlipidemia (45.64% and 30.83%, respectively), hypertension (42.19% and 24.19%), depression (17.91% and 12.68%), type 2 diabetes mellitus (17.45% and 8.44%), and obesity (14.38% and 11.57%). LIMITATIONS: A limitation of the study was that only a certain insured population was represented. CONCLUSIONS: Comorbidity rates align with those described in the literature and support the concept that psoriasispatients have high rates of cardiometabolic comorbidities. This analysis highlights the potential utility of very large insurance databases for determining comorbidity prevalence in psoriasis, which may aid health care providers in managing psoriasis.
Authors: G Damiani; N L Bragazzi; S Garbarino; V K Chattu; C M Shapiro; A Pacifico; P Malagoli; P D M Pigatto; R R Z Conic; D Tiodorovic; A Watad; M Adawi Journal: Chronobiol Int Date: 2019-10-23 Impact factor: 2.877
Authors: Maximilian Christian Schielein; Linda Tizek; Barbara Schuster; Stefanie Ziehfreund; Tilo Biedermann; Alexander Zink Journal: Acta Derm Venereol Date: 2020-05-28 Impact factor: 3.875
Authors: Shinichi Imafuku; Min Zheng; Yayoi Tada; Xibao Zhang; Colin Theng; Suganthi Thevarajah; Yi Zhao; Hae Jun Song Journal: J Dermatol Date: 2018-05-09 Impact factor: 4.005